Somaxon's Silenor meets Phase III endpoint

SOMX said Silenor doxepin met the primary endpoint of wake after sleep onset (WASO) in a Phase III trial to treat chronic insomnia. In the double-blind, placebo-controlled, U.S. study in 229 patients,...